期刊文献+

伏立诺他含量测定及其稳定性考察

下载PDF
导出
摘要 目的建立测定伏立诺他含量及有关物质的高效液相色谱法,考察光照、温度和湿度对伏立诺他质量的影响。方法采用Inertsil ODS-SP色谱柱,含量测定以0.1%磷酸溶液(三乙胺调节p H至3.0)-乙腈(70∶30)为流动相,有关物质以0.1%磷酸溶液(三乙胺调节p H至3.0)-乙腈(60∶40)为流动相;流速1.0 m L·min-1;检测波长242 nm;进样量20μL;柱温30℃;样品超声时间20 min。依据2010年版《中华人民共和国药典》二部附录"原料药与药物制剂稳定性实验指导原则"的有关技术要求进行影响因素实验。结果伏立诺他与各杂质之间均达到良好分离,伏立诺他在20.16~302.40μg·m L^-1范围内线性关系良好(r=0.999 7)。经影响因素实验后伏立诺他含量及有关物质均无明显变化。结论伏立诺他对光照、高温、高湿稳定。
出处 《医药导报》 CAS 2015年第8期1084-1086,共3页 Herald of Medicine
  • 相关文献

参考文献7

二级参考文献41

  • 1谢沐风.如何建立高效液相色谱法测定有关物质的方法[J].中国医药工业杂志,2007,38(1):45-48. 被引量:61
  • 2CRISCIONE VD, WEINSTOCK MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973 -2002 [ J]. Arch Dermatol, 2007,143 (7) :854 - 859.
  • 3FDA approves new drug for skin cancer, Zolinza[EB/OL], (2006 - 10 - 06). http ://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm 108758. htm.
  • 4ZHANG C, RICHON V, NI X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action [J]. J Invest Dermatol, 2005, 125 (5) :1045 - 1052.
  • 5MARTINEZ-IGLESIAS O, RUIZ-LLORENTE L, SANCHEZMARTINEZ R, et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer[ J]. Clin Transl Oncol, 2008, 10(7) :395 -398.
  • 6WISE LD, TURNER KJ, KERR JS, et al. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Behed rabbits[ J ]. Birth Dejects Res B Dev Reprod Toxicol, 2007, 80(1) :57 -68.
  • 7RUBIN EH, AGRAWAL NG, FRIEDMAN EJ, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer [J]. Clin Cancer Res, 2006, 12 ( 23 ) :7039 - 7045.
  • 8KELLY WK, RICHON VM, O'CONNOR O, et al. Phase I clinical trial of histone deacetylase inhibitor: saberoylanilide hydroxamic acid administered intravenously [J].Clin Cancer Res, 2003, 9(10 Pt 1 ):3578 -3588.
  • 9OLSEN EA, KIM YH, KUZEL TM, et al. Phase II b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [ J ]. J Clin Oncol, 2007, 25(21):3109-3115.
  • 10DUVIC M, TALPUR R, NI X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [ J ]. Blood, 2007, 109 (1):31-39.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部